CGTX Insider Trading (Cognition Therapeutics)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $36,000.00
Insider Selling (Last 12 Months): $0.00
Cognition Therapeutics Share Price & Price History
Current Price: $2.90
Price Change: ▲ Price Increase of +0.01 (0.35%)
As of 05/18/2022 01:00 AM ET
Copper Exploration Heating Up
From Investing Trends | Ad
Canada is already known as a miner's paradise. But British Columbia (BC) is quietly becoming the new copper hotspot. That's because copper is critical to the world's shift to renewable energy. Biden earmarked $226 billion in new infrastructure projects all requiring copper.
Discover Opportunities in the New Copper Hotspot
Cognition Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 10/13/2021 | Peggy Wallace | Director | Buy | 3,000 | $12.00 | $36,000.00 | |  |
The Incredible Dividend Map... Where Stocks Yield 26% a Year!
From Investing Daily | Ad
What’s the highest-yielding stock you’ve ever owned?
The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!
When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.
Cognition Therapeutics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 5/17/2022 | Worth Venture Partners LLC | 175,366 | $0.47M | 0.2% | N/A | 0.776% |  |
| 5/17/2022 | Prosight Management LP | 240,080 | $0.66M | 0.4% | -20.5% | 1.062% | |
| 5/13/2022 | Frontier Wealth Management LLC | 50,000 | $0.15M | 0.0% | N/A | 0.221% | |
| 5/13/2022 | Nantahala Capital Management LLC | 196,402 | $0.54M | 0.0% | -6.3% | 0.869% | |
| 5/13/2022 | Baird Financial Group Inc. | 20,393 | $56K | 0.0% | N/A | 0.090% | |
| 5/4/2022 | Commonwealth Equity Services LLC | 13,890 | $38K | 0.0% | N/A | 0.061% | |
| 4/26/2022 | Diligent Investors LLC | 30,520 | $84K | 0.0% | N/A | 0.135% | |
| 4/26/2022 | Kestra Advisory Services LLC | 238,666 | $0.66M | 0.0% | +150.9% | 1.057% | |
| 4/21/2022 | P.A.W. Capital Corp | 120,000 | $0.33M | 0.3% | +20.0% | 0.531% | |
| 4/14/2022 | Bangor Savings Bank | 18,496 | $51K | 0.0% | N/A | 0.082% | |
| 2/23/2022 | BlackRock Inc. | 7,997 | $51K | 0.0% | N/A | 0.036% | |
| 2/15/2022 | Millennium Management LLC | 56,419 | $0.36M | 0.0% | N/A | 0.256% | |
| 2/11/2022 | Renaissance Technologies LLC | 11,764 | $74K | 0.0% | N/A | 0.053% | |
| 2/10/2022 | B. Riley Financial Inc. | 30,904 | $0.20M | 0.0% | N/A | 0.140% | |
| 2/10/2022 | American Financial Group Inc. | 205,000 | $1.30M | 0.4% | N/A | 0.930% | |
| 2/10/2022 | AIGH Capital Management LLC | 25,496 | $0.16M | 0.0% | N/A | 0.116% | |
| 2/10/2022 | P.A.W. Capital Corp | 100,000 | $0.63M | 0.6% | N/A | 0.454% | |
Data available starting January 2016
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Read More on Cognition Therapeutics
Volume
15,428 shs
Average Volume
55,164 shs
Market Capitalization
$65.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Cognition Therapeutics?
Who are the major institutional investors of Cognition Therapeutics?
Which institutional investors are selling Cognition Therapeutics stock?
Within the last quarter, CGTX stock was sold by these institutional investors:
- Prosight Management LP
- Nantahala Capital Management LLC
Which institutional investors are buying Cognition Therapeutics stock?
During the last quarter, CGTX stock was bought by institutional investors including:
- Worth Venture Partners LLC
- Kestra Advisory Services LLC
- Frontier Wealth Management LLC
- Diligent Investors LLC
- Baird Financial Group Inc.
- P.A.W. Capital Corp
- Bangor Savings Bank
- Commonwealth Equity Services LLC
